These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35464463)

  • 1. Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease.
    Xu AM; Li D; Ebinger JE; Mengesha E; Elyanow R; Gittelman RM; Chapman H; Joung S; Botwin GJ; Pozdnyakova V; Debbas P; Mujukian A; Prostko JC; Frias EC; Stewart JL; Horizon AA; Merin N; Sobhani K; Figueiredo JC; Cheng S; Kaplan IM; McGovern DPB; Merchant A; Melmed GY; Braun J
    Front Immunol; 2022; 13():880190. PubMed ID: 35464463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases.
    Kappelman MD; Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda EA; Farraye FA; Boccieri ME; Firestine A; Chun KY; Fernando M; Bastidas M; Zikry M; Long MD
    Am J Gastroenterol; 2022 Mar; 117(3):462-469. PubMed ID: 35029167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine.
    Sureshchandra S; Lewis SA; Doratt BM; Jankeel A; Coimbra Ibraim I; Messaoudi I
    JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34935643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
    Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
    Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
    Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
    Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
    Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U
    Front Immunol; 2022; 13():889138. PubMed ID: 35634285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
    Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
    van Gils MJ; Lavell A; van der Straten K; Appelman B; Bontjer I; Poniman M; Burger JA; Oomen M; Bouhuijs JH; van Vught LA; Slim MA; Schinkel M; Wynberg E; van Willigen HDG; Grobben M; Tejjani K; van Rijswijk J; Snitselaar JL; Caniels TG; ; Vlaar APJ; Prins M; de Jong MD; de Bree GJ; Sikkens JJ; Bomers MK; Sanders RW
    PLoS Med; 2022 May; 19(5):e1003991. PubMed ID: 35580156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2.
    Ukey R; Bruiners N; Mishra H; Mishra PK; McCloskey D; Onyuka A; Chen F; Pinter A; Weiskopf D; Sette A; Roy J; Gaur S; Gennaro ML
    BMC Med; 2022 Jan; 20(1):32. PubMed ID: 35073931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
    PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency.
    Barmettler S; DiGiacomo DV; Yang NJ; Lam T; Naranbhai V; Dighe AS; Burke KE; Blumenthal KG; Ling M; Hesterberg PE; Saff RR; MacLean J; Ofoman O; Berrios C; St Denis KJ; Lam EC; Gregory D; Iafrate AJ; Poznansky M; Lee H; Balazs A; Pillai S; Farmer JR
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1622-1634.e4. PubMed ID: 35381395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines.
    Naranbhai V; Garcia-Beltran WF; Chang CC; Berrios Mairena C; Thierauf JC; Kirkpatrick G; Onozato ML; Cheng J; St Denis KJ; Lam EC; Kaseke C; Tano-Menka R; Yang D; Pavlovic M; Yang W; Kui A; Miller TE; Astudillo MG; Cahill JE; Dighe AS; Gregory DJ; Poznansky MC; Gaiha GD; Balazs AB; Iafrate AJ
    J Infect Dis; 2022 Apr; 225(7):1141-1150. PubMed ID: 34888672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals.
    Samanovic MI; Cornelius AR; Gray-Gaillard SL; Allen JR; Karmacharya T; Wilson JP; Hyman SW; Tuen M; Koralov SB; Mulligan MJ; Herati RS
    Sci Transl Med; 2022 Feb; 14(631):eabi8961. PubMed ID: 34874183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
    EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients.
    GeurtsvanKessel CH; Geers D; Schmitz KS; Mykytyn AZ; Lamers MM; Bogers S; Scherbeijn S; Gommers L; Sablerolles RSG; Nieuwkoop NN; Rijsbergen LC; van Dijk LLA; de Wilde J; Alblas K; Breugem TI; Rijnders BJA; de Jager H; Weiskopf D; van der Kuy PHM; Sette A; Koopmans MPG; Grifoni A; Haagmans BL; de Vries RD
    Sci Immunol; 2022 Mar; 7(69):eabo2202. PubMed ID: 35113647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
    Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
    Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.